Medical News

ICON 1: Frailty Associated with Worse One-Year Prognosis in Geriatric NSTEACS Patients undergoing Invasive Revascularization

The recently published “Improve Clinical Outcomes in high-risk patieNts with acute coronary syndrome” (ICON-1) study demonstrated invasive...

19 Oct, 2018

 
Email this page
Six-Month DAPT Non-Inferior to 12 Months DAPT in Event-Free STEMI Patients undergoing PCI with Drug-Eluting Stents

Recently published DAPT-STEMI trial demonstrated that six months dual antiplatelet therapy (DAPT) was non-inferior to DAPT for 12 months in ST-...

16 Oct, 2018

 
Email this page
Periprocedural Loading Dose of Statin May Improve Short-Term Clinical Outcomes in ACS Patients Undergoing PCI

A periprocedural loading doses of atorvastatin appeared to cut down the risk of major adverse cardiac events (MACE) at 30 days amongst acute...

05 Oct, 2018

 
Email this page
High TG Levels Associated with Increased CVD Risk among Diabetics despite Statin-Controlled LDL Levels

Diabetes patients with statin-controlled low-density lipoprotein cholesterol (LDL-C) levels but triglyceride (TG) levels between 200-499 mg/dl, have...

04 Oct, 2018

 
Email this page

Key Trials

Sacubitril/Valsartan Improves Physical and Social Activity Limitations in HFrEF Patients

Treatment with sacubitril/valsartan improves physical and social limitations in HFrEF patients in addition to the CV benefits that it provides.

Sacubitril/Valsartan vs. Enalapril in HFrEF Patients: Analyzing the Renal Impact and Associated Outcomes

The study analyzes renal effects and the associated outcomes of sacubitril/valsartan vs. enalapril in HF patients with reduced ejection fraction.  

Treatment with Macitentan Reduces Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension – SERAPHIN Study

Results of the SERAPHIN study demonstrated that treatment with macitentan resulted in significant reduction in morbidity and mortality in patients...

Initiation/Uptitration of Sacubitril/Valsartan in HFrEF Patients: Insights from the TITRATION Trial

The TITRATION trial assessed tolerability of initiating/uptitrating sacubitril/valsartan using a conservative or condensed regimen in HFrEF patients...

Slide Library

Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH

Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the...

 
Email this page
Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of...

 
Email this page
Diabetic Dyslipidemia

Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...

 
Email this page
Ambrisentan in PAH

Ambrisentan is a propanoic acid, non-sulfonamide, selective endothelin type A (ETA) receptor antagonist which is used in pulmonary arterial...

 
Email this page

Our Publications

Azmarda (Sacubitril/Valsartan) FAQs

This booklet on frequently asked questions on sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) provides...

Retefast (Reteplase) Datasheet

This datasheet provides an overview on the pharmacology, clinical efficacy, safety, indications and dosage of reteplase.

The Changing Landscape of CV Risk Reduction - Is LDL Lowering Sufficient: Questions & Answers (Dr. Michael Miller, USA)

Here is a set of questions addressed by Dr. Michael Miller, a renowned cardiologist and lipidologist during the “PROMISE” meet held in India.

Pulmonary Hypertension – An Update

This article summarises the definition, classification, pathogenesis, assessment, prognosis, diagnosis and treatment for PH.

Patient Education

Understanding Angioplasty

Angioplasty is a life-saving procedure to open up blocked or narrowed blood vessels. This document gives a brief idea about the procedure.

Managing Your Angina

It explains the causes, risk factors, symptoms and treatment options for angina, as well as the various do’s and don’t’s in a patient-friendly...

Understanding Obesity

This document explains what is obesity, what is the impact of obesity on overall health and what are the benefits of weight loss. 

Hypertension

Know more about the risk factors, associated ill-effects and tips for management of hypertension or high blood pressure. 

Poll

What percent of your patients who need oral anticoagulation, receive warfarin?
<20%
17% (2 votes)
20-40%
17% (2 votes)
40-50%
8% (1 vote)
50-70%
17% (2 votes)
70-80%
33% (4 votes)
Almost all
8% (1 vote)
Total votes: 12